announcement today about FDA clearance for use in diabetic ulcers ect.
thinking to myself
aroa still a biological product and Novosorb synthetic.
but why hasnt PNV commented or made any specific moves to market Novosorb in this space.
Aroa value the TAM for it as 1b+ in US alone.
does anyone know of any case studies or comments from management Around use to novosorb in chronic wounds with healing compromised by disease (diabetes)
cheers
Aroa Discussion
-
- There are more pages in this discussion • 43 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.38 |
Change
-0.030(1.24%) |
Mkt cap ! $1.642B | |||
| Open | High | Low | Value | Volume |
| $2.42 | $2.44 | $2.36 | $4.288M | 1.798M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 28177 | $2.37 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.38 | 26895 | 1 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| PNV (ASX) Chart |